Free Trial

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0024 +0.00 (+84.62%)
As of 07/11/2025 03:46 PM Eastern

SRNE vs. SPRB, ENVB, GLMD, ELAB, AFMD, PRFX, ADTX, PBM, OGEN, and GRI

Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Spruce Biosciences (SPRB), Enveric Biosciences (ENVB), Galmed Pharmaceuticals (GLMD), PMGC (ELAB), Affimed (AFMD), PainReform (PRFX), Aditxt (ADTX), Psyence Biomedical (PBM), Oragenics (OGEN), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry.

Sorrento Therapeutics vs. Its Competitors

Spruce Biosciences (NASDAQ:SPRB) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Sorrento Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Sorrento Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spruce Biosciences-555.23% -62.10% -47.49%
Sorrento Therapeutics N/A N/A N/A

Spruce Biosciences currently has a consensus price target of $1.75, suggesting a potential upside of 1,857.49%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Sorrento Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Spruce Biosciences' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Spruce Biosciences Neutral
Sorrento Therapeutics Neutral

Spruce Biosciences has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce Biosciences$4.91M0.77-$47.92M-$1.32-0.07
Sorrento Therapeutics$60.32M0.02-$572.84MN/AN/A

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spruce Biosciences has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Summary

Spruce Biosciences beats Sorrento Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

MetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.32M$216.39M$5.56B$9.10B
Dividend YieldN/AN/A5.06%4.02%
P/E RatioN/AN/A28.2620.26
Price / Sales0.02253.11427.70153.06
Price / CashN/A22.4437.1257.67
Price / BookN/A6.158.045.49
Net Income-$572.84M-$96.61M$3.19B$250.45M
7 Day PerformanceN/A12.02%3.62%4.79%
1 Month PerformanceN/A11.51%5.98%9.59%
1 Year PerformanceN/A7.49%29.39%16.41%

Sorrento Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
0.3641 of 5 stars
$0.00
+84.6%
N/A-75.0%$1.32M$60.32M0.00800
SPRB
Spruce Biosciences
2.0647 of 5 stars
$0.07
+0.7%
$1.75
+2,313.8%
-84.4%$3.06M$4.91M-0.0820Gap Down
ENVB
Enveric Biosciences
2.6962 of 5 stars
$1.21
-2.4%
$10.00
+726.4%
-83.1%$3.06MN/A-0.0320
GLMD
Galmed Pharmaceuticals
1.4231 of 5 stars
$1.84
+1.7%
N/A-47.3%$2.99MN/A-0.1120Positive News
ELAB
PMGC
0.5891 of 5 stars
$2.16
+0.9%
N/A-99.7%$2.94M$1.71M0.0018News Coverage
AFMD
Affimed
2.8543 of 5 stars
$0.18
-34.9%
$3.62
+1,895.9%
-96.5%$2.92M$877K0.00200Gap Down
High Trading Volume
PRFX
PainReform
0.6664 of 5 stars
$1.44
+2.1%
N/A-28.8%$2.84MN/A-0.014Trending News
ADTX
Aditxt
N/A$1.28
-3.8%
N/A-100.0%$2.82M$130K0.0060
PBM
Psyence Biomedical
0.9889 of 5 stars
$5.33
+8.6%
N/A-97.2%$2.80MN/A0.00N/AGap Up
OGEN
Oragenics
0.0711 of 5 stars
$3.82
-5.7%
N/A-95.8%$2.73M$40K-0.545Gap Down
GRI
GRI Bio
3.0512 of 5 stars
$1.29
+1.6%
$22.00
+1,605.4%
-94.4%$2.72MN/A-0.111Positive News

Related Companies and Tools


This page (NASDAQ:SRNE) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners